(Q52841019)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Colin A Purdie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Robert C. Stein

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sarah E. Pinder

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

J M S Bartlett

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

S Lane

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Francis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A M Thompson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Translational Subgroup of the NCRI Breast Clinical Studies Group

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

23 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pathology

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

161-167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24062360%20AND%20SRC:MED&resulttype=core&format=json

HER2 testing in the UK: further update to recommendations

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819

Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201819